• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Modus Therapeutics

0.44 SEK

+5.01 %

Less than 1K followers

MODTX

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+5.01 %
-3.93 %
+53.31 %
+44.74 %
+21.21 %
-19.99 %
-51.89 %
-
-78.74 %

Modus Therapeutics operates in biotechnology. The product portfolio includes the drug candidate sevuparin. The company's focus is to develop sevuparin for patients with sepsis, septic shock and other conditions with systemic inflammation. In addition to its core business, it also offers service and related ancillary services. The business and related research are conducted with the largest presence in Sweden.

Read more
Market cap
65.43M SEK
Turnover
56.96K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
All
Press releases
3rd party
ShowingAll content types

Financial calendar
26/8
2026

Interim report Q2'26

24/11
2026

Interim report Q3'26

24/2
2027

Annual report '26

Press release6/3/2026, 9:28 AM

Analyst Group: Aktieanalys på Modus Therapeutics - Stärkt position inför proof-of-concept-data

Modus Therapeutics
Regulatory press release5/28/2026, 10:30 AM

Årsstämma i Modus Therapeutics Holding AB (publ)

Modus Therapeutics
Regulatory press release5/28/2026, 10:30 AM

Annual General Meeting in Modus Therapeutics Holding AB (publ)

Modus Therapeutics

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release5/26/2026, 3:35 PM

Analyst Group: Analyst Group kommenterar Modus Therapeutics Q1-rapport

Modus Therapeutics
Regulatory press release5/26/2026, 6:00 AM

Modus Therapeutics publicerar delårsrapport för Q1 2026

Modus Therapeutics
Regulatory press release5/26/2026, 6:00 AM

Modus Therapeutics publishes interim report for Q1 2026

Modus Therapeutics
Press release5/21/2026, 12:30 PM

Modus Therapeutics presenterar sevuparin-data vid European Iron Club Meeting 2026 i Dublin

Modus Therapeutics
Press release5/21/2026, 12:30 PM

Modus Therapeutics to present sevuparin data at the European Iron Club Meeting 2026 in Dublin

Modus Therapeutics
Press release5/13/2026, 8:15 AM

Modus Therapeutics presenterar prekliniska data om sevuparin vid CKD med anemi på EHA2026 i Stockholm

Modus Therapeutics
Press release5/13/2026, 8:15 AM

Modus Therapeutics to present preclinical data on sevuparin in CKD with anemia at EHA2026 in Stockholm

Modus Therapeutics
Press release4/28/2026, 2:07 PM

Analyst Group: Analyst Group kommenterar utfallet av TO 2026 i Modus Therapeutics

Modus Therapeutics
Regulatory press release4/27/2026, 8:15 PM

Modus offentliggör utfall av nyttjande av teckningsoptioner av serie TO 2026 och tillförs cirka 9,5 MSEK

Modus Therapeutics
Regulatory press release4/27/2026, 8:15 PM

Modus announces outcome of exercise of warrants of series TO 2026 and receives approximately SEK 9.5 million

Modus Therapeutics
Regulatory press release4/27/2026, 12:00 PM

Kallelse till årsstämma i Modus Therapeutics Holding

Modus Therapeutics
Regulatory press release4/27/2026, 12:00 PM

Notice to Annual General Meeting in Modus Therapeutics Holding

Modus Therapeutics
Press release4/15/2026, 7:57 AM

Analyst Group: Analyst Group kommenterar att KDventures nyttjar samtliga sina TO2 i Modus Therapeutics

Modus Therapeutics
Regulatory press release4/15/2026, 6:00 AM

Modus Therapeutics Holding AB (publ) offentliggör årsredovisning för räkenskapsåret 2025

Modus Therapeutics
Regulatory press release4/15/2026, 6:00 AM

Modus Therapeutics Holding AB (publ) publishes annual report for the financial year 2025

Modus Therapeutics
Regulatory press release4/14/2026, 2:00 PM

KDventures AB tecknar samtliga sina teckningsoptioner av serie 2025/2026 i Modus Therapeutics

Modus Therapeutics
Regulatory press release4/14/2026, 2:00 PM

KDventures AB subscribes for all of its warrants of series 2025/2026 in Modus Therapeutics

Modus Therapeutics